NovaSecta, an R&D advisory company located in England that specializes in advising smaller and mid-sized biopharmas, announced an alliance with a China CRO consortium – the coalition formed by Sundia MediTech and HD BioSciences in 2007. NovaSecta seeks to provide its mid-sized clients with R&D alternatives. These can include managing its R&D efforts or establishing strategic outsourcing partnerships. NovaSecta has also formed a multi-company R&D program that comprises eight mid-sized biopharmas in seven European countries. More details...